MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

In patients with an increased risk of adverse reactions, e.g. a history of gastrointestinal disease or risks for cardiovascular disease, the treatment should be started at 7.5 mg/day and increased to 15 mg/day only if clinically justified. daca sunteti alergic (hipersensibil) la acid acetilsalicilic sau la alte medicamente antiinflamatoare nesteriodiene (AINS); Not all of these side effects have been reported with MOVALIS but have been seen with similar medicines. Caution should be exercised when treating patients with a history of upper gastrointestinal disease and in patients receiving treatment with anticoagulants. Patients with GI symptoms should be monitored. Movalis therapy should cease if peptic ulceration or GI ulceration or bleeding occurs.

tulburări ale numărului elementelor sanguine, incluzând formula leucocitară, leucopenia şi trombocitopenia. Administrarea concomitentă a unui medicament potenţial mielotoxic, metotrexat în special, pare a fi un factor favorizant pentru apariţia citopeniei. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.Hypertension interaction There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of colestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%. Meloxicam is eliminated from the body with a mean elimination half-life of 20 hours. Plasma clearance ranges from 7-9 mL/min.

Before you take it

If any of the following happen, stop taking it and tell your doctor immediately, or go to Accident and Emergency at the nearest hospital:

Patients with signs and/or symptoms suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Movalis. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc), Movalis should be discontinued. tulburări tranzitorii ale parametrilor funcţiei hepatice (de exemplu, creşterea transaminazelor sau a bilirubinei), eructaţii, esofagită, ulcer gastroduodenal, sângerări gastrointestinale oculte sau macroscopiceContracepţie: Scăderea eficacităţii dispozitivelor intrauterine de către AINS a fost raportată anterior, dar este necesară o confirmare ulterioară. Concomitant administration of drugs known to inhibit CYP2C9 (e.g. sulfaphenazole, sulfinpyrazone, sulfamethoxazole and fluconazole).